Q2 2025 Uniqure NV Earnings Call Transcript
Key Points
- uniQure NV (QURE) has made significant progress in advancing AMT-130 for Huntington's disease, receiving breakthrough therapy designation from the FDA.
- The company has achieved regulatory alignment with the FDA on statistical analysis and CMC requirements for AMT-130, paving the way for a planned BLA submission in early 2026.
- uniQure NV (QURE) is preparing for a potential commercial launch of AMT-130 in 2026, with strategic hires and investments in commercial operations.
- Encouraging early data from AMT-260 for mesial temporal lobe epilepsy showed a 92% reduction in seizure frequency, generating strong interest in the epilepsy community.
- The company maintains a strong financial position with $377 million in cash, cash equivalents, and investment securities, expected to fund operations into the second half of 2027.
- Revenue for the second quarter of 2025 decreased to $5.3 million from $11.1 million in the same period in 2024, primarily due to declines in collaboration and contract manufacturing revenue.
- Research and development expenses increased by $1.7 million compared to the same period in 2024, driven by higher external program spending and contingent consideration.
- The company faces challenges in trial recruitment for AMT-260, despite increased interest following positive early data.
- There is uncertainty regarding the regulatory path for AMT-130 in Europe, as discussions with EMA have not yet occurred.
- The company has not conducted formal analysis on the 2.5-year data for AMT-130, leaving some uncertainty about the consistency of results leading up to the September update.
Good day and thank you for standing by. Welcome to the Uniqure second-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Chiara Russo, Senior Director of Investor Relations. Please go ahead.
Good morning and thank you for joining us for Uniqure second quarter of 2025 earnings call. Earlier this morning, Uniqure released its financial results for the second quarter of 2025. And our press release is available on the investors and media section of our website at uniqure.com. Our 10-Q was also filed with the SEC earlier this morning.
Joining me on the call today are Matt Kapusta, Chief Executive Officer; Dr. Walid Abi-Saab, Chief Medical Officer; and Christian Klemt, Chief Financial Officer. After our formal remarks, we will open up the call for Q&A.
Before we begin, please know that we will be making forward-looking statements during this investor
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
